Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala joined a Virtual Investor “What This Means” interview on Feb. 11, 2026 to discuss the company’s expanded ADC pipeline, a recent patent filing, and the introduction of second ADC candidate AKTX-102 targeting CEACAM5 tumors.
The segment reviewed the scalability of Akari’s PH1-powered ADC platform, the company’s differentiated CEACAM5 antibody construct, execution priorities for lead program AKTX-101 as it advances toward IND and CTA submissions, and the strategic role of a growing patent estate to support partnering and long-term value creation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AKTX gained 1.45%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.9% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $174K to the company's valuation, bringing the market cap to $12M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AKTX was down 2.34% while close peers showed a mixed tape: QTTB and LIXT fell 8.31% and 9.73%, RNTX slipped 0.87%, but KZR and ALLR gained 1.14% and 8.15%. No clear sector-wide pattern emerged.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Investor webinar | Positive | -2.2% | Corporate overview of ADC platform and AKTX-101/102 development plans. |
| Jan 26 | Patent & pipeline | Positive | -0.5% | Filed key patent and introduced second ADC program AKTX-102 targeting CEACAM5. |
| Jan 09 | CEO strategy update | Positive | -0.3% | CEO Corner review of 2025 progress and clinical transition plans for 2026. |
| Jan 08 | Conference presentation | Positive | -1.7% | Announcement of in-person presentation at 2026 Biotech Showcase. |
| Dec 30 | Year-end letter | Positive | +2.3% | End-of-year letter detailing PH1-based ADC progress and 2026 IND plans. |
Recent company communications on ADC strategy and events have generally been followed by modest downside in the share price, despite ostensibly positive content.
Over the last few months, Akari has steadily communicated its transition into an ADC-focused oncology company. Updates included a year-end letter on PH1 payload progress, multiple conference and webinar participations, and a key patent filing plus unveiling of AKTX-102. These events reinforced plans for first-in-human trials around late 2026/early 2027. However, four of the last five news items with positive tone were followed by small negative price moves, suggesting investor skepticism or financing overhang.
Regulatory & Risk Context
The company has an effective S-3 shelf filed on 2025-07-29, with recorded usage via at least two 424B5 offerings, providing a mechanism for additional capital raises without a new full registration statement.
Market Pulse Summary
This announcement highlights continued messaging around Akari’s ADC strategy, emphasizing the addition of AKTX-102, CEACAM5 targeting, and plans for IND/CTA submissions for AKTX-101. It builds on earlier patent filings, financings, and the shift to an oncology focus. Investors may watch for concrete clinical milestones, progress toward first-in-human studies, and how the company navigates its financing structure and Nasdaq listing requirements as key future checkpoints.
Key Terms
antibody drug conjugates medical
adcs medical
rna-splicing payloads medical
cta regulatory
first-in-human medical
ceacam5 medical
spliceosome-modulating payload medical
AI-generated analysis. Not financial advice.
CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy
Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as it advances towards first-in-human studies
Watch the “What This Means” video here
TAMPA, Fla. and LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that Abizer Gaslightwala, CEO of Akari Therapeutics, participated in a Virtual Investor “What This Means” interview focused on the Company’s expanding ADC pipeline and intellectual property strategy.
As part of the segment, Mr. Gaslightwala discussed Akari’s recently announced patent filing and the introduction of AKTX-102, the Company’s second ADC pipeline candidate targeting CEACAM5-expressing solid tumors. The discussion highlighted how this milestone underscores the scalability of Akari’s PH1-powered ADC platform and its ability to generate multiple differentiated therapeutic programs.
Mr. Gaslightwala also addressed Akari’s differentiated approach to CEACAM5 through its novel antibody construct combined with the PH1 spliceosome-modulating payload, as well as the Company’s execution priorities as its lead program, AKTX-101, advances toward IND and CTA submission and first-in-human studies. In addition, the segment explored the strategic importance of Akari’s growing patent estate in supporting long-term value creation and potential partnering opportunities.
The Virtual Investor “What This Means” segment featuring Akari Therapeutics is now available here.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers. For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
What did Akari Therapeutics (AKTX) say about AKTX-101 in the Feb 11, 2026 investor interview?
What is AKTX-102 and how does it expand Akari Therapeutics' pipeline (AKTX)?
How did Akari describe the role of its PH1 spliceosome-modulating payload in the Feb 11, 2026 interview?
What did Akari Therapeutics say about its recent patent filing and IP strategy (AKTX)?
Where can investors watch the Akari Therapeutics (AKTX) Virtual Investor "What This Means" segment?
